{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T23:07:23Z","timestamp":1649200043478},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,4,8]],"date-time":"2014-04-08T00:00:00Z","timestamp":1396915200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-247","type":"journal-article","created":{"date-parts":[[2014,4,8]],"date-time":"2014-04-08T21:06:02Z","timestamp":1396991162000},"source":"Crossref","is-referenced-by-count":4,"title":["Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia"],"prefix":"10.1186","volume":"14","author":[{"given":"Christel CLM","family":"Boons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora L","family":"Swart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lonneke","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen JWM","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline G","family":"Hugtenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,8]]},"reference":[{"key":"4413_CR1","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1053\/j.seminhematol.2006.12.007","volume":"44","author":"RH Alvarez","year":"2007","unstructured":"Alvarez RH, Kantarjian H, Cortes JE: The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol. 2007, 44: S4-S14.","journal-title":"Semin Hematol"},{"key":"4413_CR2","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F, Goldman JM, Hochhaus H, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J, Reynolds J, Gathmann I, Larson RA, Druker BJ: International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009, 114: 1126-(ASH Meeting): abstract","journal-title":"Blood"},{"key":"4413_CR3","unstructured":"Tasigna: European Public Assessment Report - Product Information. Annex I - Summary of product characteristics. 2013"},{"key":"4413_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.leukres.2012.01.021","volume":"36","author":"A Gater","year":"2012","unstructured":"Gater A, Heron L, Betz-Webb L, Coombs J, Simmons J, Guilhot F, Rea D: Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res. 2012, 36: 817-825. 10.1016\/j.leukres.2012.01.021.","journal-title":"Leuk Res"},{"key":"4413_CR5","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon F, Eliasson L, Milojkovic D, Bua M, Apperley J, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad J: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010, 28: 2381-2388. 10.1200\/JCO.2009.26.3087.","journal-title":"J Clin Oncol"},{"key":"4413_CR6","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T, Abraham I: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009, 113: 5401-5411. 10.1182\/blood-2008-12-196543.","journal-title":"Blood"},{"key":"4413_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/ajh.23180","volume":"87","author":"EJ Jabbour","year":"2012","unstructured":"Jabbour EJ, Kantarjian H, Eliasson L, Cornelison AM, Marin D: Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012, 87: 687-691. 10.1002\/ajh.23180.","journal-title":"Am J Hematol"},{"key":"4413_CR8","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","volume":"35","author":"L Eliasson","year":"2011","unstructured":"Eliasson L, Clifford S, Barber N, Marin D: Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011, 35: 626-630. 10.1016\/j.leukres.2010.10.017.","journal-title":"Leuk Res"},{"key":"4413_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.suponc.2011.08.001","volume":"10","author":"M Cornelison","year":"2012","unstructured":"Cornelison M, Jabbour EJ, Welch MA: Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol. 2012, 10: 14-24. 10.1016\/j.suponc.2011.08.001.","journal-title":"J Support Oncol"},{"key":"4413_CR10","first-page":"237","volume":"8","author":"GJ Ossenkoppele","year":"2011","unstructured":"Ossenkoppele GJ, Janssen JJWM, Posthuma EF, Falkenburg JHF, Bos GMJ, Petersen EJ, Schattenberg AV, Verhoef G, Vellenga E, Cornelissen JJ: Aanbevelingen voor de behandeling van chronische myelo\u00efde leukemie 2011 [Guidelines for treatment of chronic myeloid leukemia 2011]. Ned Tijdschr Hematol. 2011, 8: 237-247.","journal-title":"Ned Tijdschr Hematol"},{"issue":"7","key":"4413_CR11","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mds228","volume":"23","author":"M Baccarani","year":"2012","unstructured":"Baccarani M, Pileri S, Steegmann JL, Muller M, Soverini S, Dreyling M: Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012, 23 (7): vii72-vii77.","journal-title":"Ann Oncol"},{"key":"4413_CR12","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010, 362: 2260-2270. 10.1056\/NEJMoa1002315.","journal-title":"N Engl J Med"},{"key":"4413_CR13","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, Le CP, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010, 362: 2251-2259. 10.1056\/NEJMoa0912614.","journal-title":"N Engl J Med"},{"key":"4413_CR14","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1200\/JCO.2011.36.0693","volume":"29","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Kantarjian HM, O\u2019Brien S, Shan J, Quintas-Cardama A, Garcia-Manero G, Rios MB, Cortes JE: Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?. J Clin Oncol. 2011, 29: 4260-4265. 10.1200\/JCO.2011.36.0693.","journal-title":"J Clin Oncol"},{"key":"4413_CR15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1200\/JCO.2010.31.3619","volume":"29","author":"J Cortes","year":"2011","unstructured":"Cortes J, Hochhaus A, Hughes T, Kantarjian H: Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol. 2011, 29: 524-531. 10.1200\/JCO.2010.31.3619.","journal-title":"J Clin Oncol"},{"key":"4413_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00228-012-1385-4","volume":"69","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Yin OQ, Sallas WM, le Coutre PD, Woodman RC, Ottmann OG, Baccarani M, Kantarjian HM: Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Eur J Clin Pharmacol. 2013, 69: 813-823. 10.1007\/s00228-012-1385-4.","journal-title":"Eur J Clin Pharmacol"},{"key":"4413_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/FTD.0b013e31827d76ce","volume":"35","author":"AJ Wilhelm","year":"2013","unstructured":"Wilhelm AJ, Klijn A, den Burger JC, Visser OJ, Veldkamp AI, Janssen JJ, Swart EL: Clinical validation of dried blood spot sampling in therapeutic drug monitoring of ciclosporin A in allogeneic stem cell transplant recipients: direct comparison between capillary and venous sampling. Ther Drug Monit. 2013, 35: 92-95. 10.1097\/FTD.0b013e31827d76ce.","journal-title":"Ther Drug Monit"},{"key":"4413_CR18","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.jchromb.2009.03.024","volume":"877","author":"AJ Wilhelm","year":"2009","unstructured":"Wilhelm AJ, den Burger JC, Vos RM, Chahbouni A, Sinjewel A: Analysis of cyclosporin A in dried blood spots using liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009, 877: 1595-1598. 10.1016\/j.jchromb.2009.03.024.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"4413_CR19","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","volume":"68","author":"RA Larson","year":"2011","unstructured":"Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD: Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph\u2009+\u2009chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2011, 68: 723-733.","journal-title":"Eur J Clin Pharmacol"},{"key":"4413_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3109\/0284186X.2013.844353","volume":"53","author":"L Timmers","year":"2014","unstructured":"Timmers L, Boons CCLM, Kropff F, van de Ven PM, Swart EL, Smit EF, Zweegman S, Kroep JR, Timmer-Bonte JN, Boven E, Hugtenburg JG: Adherence and patients\u2019 experiences with the use of oral anticancer agents. Acta Oncol. 2014, 53: 259-267. 10.3109\/0284186X.2013.844353.","journal-title":"Acta Oncol"},{"key":"4413_CR21","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/01.TP.0000110412.20050.36","volume":"77","author":"JA Butler","year":"2004","unstructured":"Butler JA, Peveler RC, Roderick P, Horne R, Mason JC: Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation. 2004, 77: 786-789. 10.1097\/01.TP.0000110412.20050.36.","journal-title":"Transplantation"},{"key":"4413_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/qhc.0100135","volume":"10","author":"R Horne","year":"2001","unstructured":"Horne R, Hankins M, Jenkins R: The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care. 2001, 10: 135-140. 10.1136\/qhc.0100135.","journal-title":"Qual Health Care"},{"key":"4413_CR23","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0895-4356(98)00097-3","volume":"51","author":"NK Aaronson","year":"1998","unstructured":"Aaronson NK, Muller M, Essink-Bot ML, Fekkes M, Sanderman R, te Velde A, Verrips E: Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in Community and Chronic Disease Populations. J Clin Epidemiol. 1998, 51: 1055-1068. 10.1016\/S0895-4356(98)00097-3.","journal-title":"J Clin Epidemiol"},{"key":"4413_CR24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/rheumatology\/37.8.862","volume":"37","author":"NP Hurst","year":"1998","unstructured":"Hurst NP, Ruta DA, Kind P: Comparison of the MOS short form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. Br J Rheumatol. 1998, 37: 862-869. 10.1093\/rheumatology\/37.8.862.","journal-title":"Br J Rheumatol"},{"key":"4413_CR25","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jpsychores.2005.10.020","volume":"60","author":"E Broadbent","year":"2006","unstructured":"Broadbent E, Petrie KJ, Main J, Weinman J: The brief illness perception questionnaire. J Psychosom Res. 2006, 60: 631-637. 10.1016\/j.jpsychores.2005.10.020.","journal-title":"J Psychosom Res"},{"key":"4413_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08870449908407311","volume":"14","author":"R Horne","year":"1999","unstructured":"Horne R, Weinman J, Hankins M: The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999, 14: 1-24. 10.1080\/08870449908407311.","journal-title":"Psychol Health"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-247\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T12:48:27Z","timestamp":1597668507000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,8]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["4413"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-247","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,8]]},"article-number":"247"}}